Dr. Postow on Nivolumab Combined With Ipilimumab in Melanoma

Michael Postow, MD
Published: Thursday, Mar 31, 2016



Michael Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for the treatment of patients with melanoma.

The combination regimen has shown significant promise for patients, Postow explains. Phase I data showed that the regimen demonstrates a very high response rate in patients, while long-term follow-up results have shown impressive survival benefits. The combination has been tested against both nivolumab and ipilimumab as single agents.

Phase III data of the CheckMate-067 trial, presented at the 2015 ASCO Annual Meeting, includes progression-free survival and overall response rates. However, Postow is anticipating the overall survival data.


Michael Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for the treatment of patients with melanoma.

The combination regimen has shown significant promise for patients, Postow explains. Phase I data showed that the regimen demonstrates a very high response rate in patients, while long-term follow-up results have shown impressive survival benefits. The combination has been tested against both nivolumab and ipilimumab as single agents.

Phase III data of the CheckMate-067 trial, presented at the 2015 ASCO Annual Meeting, includes progression-free survival and overall response rates. However, Postow is anticipating the overall survival data.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Evolving Roles for Targeted Melanoma Therapies: Assessing Rapid Progress in the Field and Looking Toward Future CombinationsFeb 28, 20191.5
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x